MCC478 is a nucleotide analogue which has entered phase I studies, and shown comparable efficacy to Epivir-HBV. In cell cultures it appears more potent than adefovir and up to 100 times more potent than Epivir-HBV. In mice, MCC478 was less efficacious than adefovir which may have been related to problems of exposure to the drug, although in infected ducks MCC478 had similar efficacy to Epivir-HBV and adefovir.
发表于 2003-9-4 07:41
